Tag Archives: Trial

Here’s Why Emerging Marijuana Stock Cara Therapeutics Inc. Surged

Here’s Why Emerging Marijuana Stock Cara Therapeutics Inc. Surged

Here’s Why Emerging Marijuana Stock Cara Therapeutics Inc. Surged

Shares of Cara Therapeutics Inc., a clinical-stage biotech company with a focus on treating pain and pruritus, rocketed higher by as much as 11% during Wednesday’s trading session after providing an update to its phase 3 trial involving kappa opioid receptor agonist CR845.

Seizures

Cannabis Derivative Cannabidiol Reduces Seizures in Severe Epilepsy Disorder

NEW YORK, May 24, 2017 /Weed Wire/ – After years of anecdotal claims about its benefits, the cannabis derivative cannabidiol reduced seizure frequency 39 percent for patients with Dravet syndrome—a rare, severe form of epilepsy—in the first large-scale, randomized clinical trial for the compound.

Zynerba

Zynerba Pharmaceuticals Announces Completion of Enrollment for ZYN002 in Two Phase 2 Clinical Trials for Epilepsy and Osteoarthritis

DEVON, Penn., March 13, 2017 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures.

Science and Medicine of Cannabis: Coping With PTSD

Science and Medicine of Cannabis: Coping With PTSD

Sue Sisley, M.D., is leading the way in studying medical marijuana and post-traumatic stress disorder. In her talk, “Coping With PTSD,” hear Sisley discuss the first clinical trial to study the effects of medical marijuana in the treatment of post-traumatic stress disorder in military veterans.

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.

Police

Crime & Punishment: The Story of Marijuana and Militarized Police

The combat between sovereign authorities on the one hand and the people who pursue the drug trade on the other—inclusive of the marijuana trade—where it remains criminal, has become frighteningly militarized in recent decades.


Top